Bullfrog AI Holdings, Inc. BFRG

Full chart Compare
Set alert

Price alert · BFRG

All alert types
0.52 USD +0.03 (+5.40%)

At closeNov 3, 2026, 4:40 PM EST

0.50 -0.02 -4.43%

After hours · Nov 3, 4:40 PM ET

0.4974 Day range 0.53
0.425 52-week range 1.96
YTD
-40.75%
1 year
-54.90%
Market cap
9.70M
Revenue (ttm)
65.00K
EPS (ttm)
-0.46
Shares out
8.71M
YTD return
-40.75%
1-year return
-54.90%
Volume
200.10K
Avg volume
5.37M
Open
0.5037
Previous close
0.4964
Day's range
0.4974 – 0.53
52-week range
0.425 – 1.96

5m +0.0153 (+3.18%)

0.46000.48000.50000.5200Oct 27Oct 28Oct 29Oct 30Nov 20.4964

Key statistics

Enterprise value
15.37M
PEG ratio
0.00
Price / sales
286.86
Price / book
5.04
Dividend yield
0.00%
Payout ratio
0.00%
Revenue growth
0.00%
Free cash flow
-3.42M
Total cash
5.61M
Total debt
341.04K
Return on equity
-117.94%
Short % of float
5.69%
50-day average
2.33
200-day average
2.64

Next earnings

Consensus EPS estimate 0.00.

Earnings history

Financials — quick view

All financials
BFRG Revenue — quarterly 215.38K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BFRG Net income — quarterly -1.37M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
BFRG EPS — quarterly -0.07
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

About Bullfrog AI Holdings, Inc.

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

Sector
Healthcare
Industry
Health Information Services
Country
United States

News

Your note

Sign in to keep a note on BFRG — it syncs with the Stock Master app.

Insider holders

BFRG insider holders
InsiderRelationLatest transactionDateShares held
ENRIGHT WILLIAMDirectorPurchaseJun 13, 20235,000
SINGH VININDERChief Executive OfficerSaleOct 8, 20242,442,450

Institution ownership

BFRG institution ownership
Holder% heldSharesValueReported
Vanguard Group Inc1.42%124,147265.67KSep 29, 2024
Fortem Financial Group, LLC0.59%51,400110.00KSep 29, 2024
Geode Capital Management, LLC0.41%35,95376.94KSep 29, 2024
Raymond James & Associates, Inc.0.17%15,00032.10KSep 29, 2024
Xtx Topco Ltd0.12%10,31722.08KSep 29, 2024
Morgan Stanley0.07%6,47613.86KSep 29, 2024

Fund ownership

BFRG fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.09%95,347204.04KSep 29, 2024
Vanguard Extended Market Index Fund0.33%28,80061.63KSep 29, 2024
Fidelity Extended Market Index Fund0.29%25,38154.31KOct 30, 2024
Fidelity Total Market Index Fund0.08%6,91014.79KOct 30, 2024
Fidelity Series Total Market Index Fund0.08%6,58414.09KOct 30, 2024
Fidelity NASDAQ Composite Index Fund0.04%3,4077.29KOct 30, 2024